Pseudomonas vaccine - Provalis

Drug Profile

Pseudomonas vaccine - Provalis

Alternative Names: Psuedostat

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Provalis
  • Developer Provalis; University of Newcastle, Australia
  • Class Bacterial vaccines; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bronchiectasis; Chronic bronchitis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 17 Feb 2003 Suspended - Phase-I for Cystic fibrosis-associated respiratory tract infections in Australia (PO)
  • 17 Feb 2003 Suspended - Preclinical for Pseudomonal infections in Australia (PO)
  • 06 Sep 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top